Sugi Predict

Sugi Predict / Compounds / SCHEMBL1768922

SCHEMBL1768922

SCHEMBL1768922

Nc1c([N+](=O)[O-])cccc1C(F)(F)F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.46
▸ TDP1 Q9NUW8 3/20 0.45
▸ GPR35 Q9HC97 2/20 0.44
▸ TSHR P16473 3/20 0.40
▸ MAPT P10636 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ LMNA P02545 1/20 0.39
▸ S100A4 P26447 1/20 0.39
▸ PDE7A Q13946 1/20 0.39
▸ KIF11 P52732 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ HIF1A Q16665 1/20 0.38
▸ TXNRD1 Q16881 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30152700 1.00 ALDH1A1 (0.46) ALDH1A1TDP1GPR35TSHRMAPT
SCHEMBL1999849 0.80 ALDH1A1 (0.50) ALDH1A1TDP1GPR35TSHRSMN1; SMN2
SCHEMBL30627320 0.80 ALDH1A1 (0.50) ALDH1A1TDP1GPR35TSHRSMN1; SMN2
SCHEMBL65199 0.80 TDP1 (0.61) ALDH1A1TDP1GPR35TSHRMAPT
SCHEMBL6515 0.79 TDP1 (0.47) ALDH1A1TDP1GPR35TSHRSMN1; SMN2
SCHEMBL1459395 0.79 TSHR (0.53) ALDH1A1TDP1GPR35TSHRSMN1; SMN2
SCHEMBL1995565 0.79 TDP1 (0.47) ALDH1A1TDP1GPR35TSHRSMN1; SMN2
SCHEMBL29805067 0.79 TDP1 (0.47) ALDH1A1TDP1GPR35TSHRSMN1; SMN2
SCHEMBL103562 0.78 GPR35 (0.64) ALDH1A1TDP1GPR35MAPTSMN1; SMN2
SCHEMBL7775267 0.78 ALDH1A1 (0.46) ALDH1A1TDP1GPR35TSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7539006-B2 Electrolytic solution for driving electrolytic capacitor and electrolytic capacitor RUBYCON CORPORATION (JP) 2009-05-26 — — US claimed
US-20070029529-A1 Electrolytic solution for driving electrolytic capacitor and electrolytic capacitor KOMATSU AKIHIKO 2007-02-08 — — US claimed
US-20040245105-A1 Electrolyte solution for driving electrolytic capacitor and electrolytic capacitor RUBYCON CORPORATION (JP) 2004-12-09 — — US claimed
EP-1437749-A1 ELECTROLYTE SOLUTION FOR DRIVING ELECTROLYTIC CAPACITOR AND ELECTROLYTIC CAPACITOR Rubycon Corporation (JP) 2004-07-14 — — EP claimed
US-20250163038-A1 CBL-B MODULATORS AND USES THEREOF NIMBUS CLIO, INC. 2025-05-22 — — US disclosed
CN-116120190-B Method for preparing o-nitroaniline compound and application of o-nitroaniline compound 邵阳学院 2024-08-23 — — CN disclosed
EP-4359381-A1 CBL-B MODULATORS AND USES THEREOF Nimbus Clio, Inc. (US) 2024-05-01 — — EP disclosed
CN-117858865-A CBL-B modulators and uses thereof 林伯士克莱奥公司 2024-04-09 — — CN disclosed
CN-116120190-A Method for preparing o-nitroaniline compound and application of o-nitroaniline compound 邵阳学院 2023-05-16 — — CN disclosed
EP-3676278-B1 CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS BRISTOL MYERS SQUIBB CO (US) 2023-04-12 — — EP disclosed
WO-2022272248-A1 CBL-B MODULATORS AND USES THEREOF NIMBUS CLIO, INC. (US) 2022-12-29 — — WO disclosed
CN-109310607-B Use of azomethine-type compounds bearing quinoline derivative units for dyeing keratin fibres 莱雅公司 2022-04-15 — — CN disclosed
CN-1265395-A Benzotriazole UV absorbent CIBA SC HOLDING AG (CH) 2000-09-06 — — CN disclosed
EP-0635483-B1 Process for preparing nitroaniline derivatives SUMITOMO CHEMICAL CO (JP) 1997-10-22 — — EP disclosed
US-5466871-A Amination of a nitrobenzene with a hydroxylamine SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1995-11-14 — — US disclosed
EP-0635483-A1 Process for preparing nitroaniline derivatives SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1995-01-25 — — EP disclosed
EP-0280156-A2 Process for the preparation of acetoacetylarylamides-heteroarylamides respectively of deactived aromatic compounds HOECHST AKTIENGESELLSCHAFT (DE) 1988-08-31 — — EP disclosed
US-4096185-A P-CHLOROBENZOTRIFLUORIDE, AMMONIA, COPPER COMPOUND CATALYST E. I. DU PONT DE NEMOURS AND COMPANY (US) 1978-06-20 — — US disclosed
US-4064127-A Trifluoromethyl dibenzo[a,c]phenazines as immune regulants ELI LILLY AND COMPANY (US) 1977-12-20 — — US disclosed
US-4024142-A 9-(TRIFLUOROMETHYL)ACENAPHTHO(1,2-B) QUINOXALINE ELI LILLY AND COMPANY (US) 1977-05-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163038-A1 CBL-B MODULATORS AND USES THEREOF CBLB, CBL, CBLC ALDH1A1 4185/4885TDP1 749/4885GPR35 4051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.